JIANMIN PHARMACEUTICAL GROUP CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 56.35 CNY | +1.28% |
|
-0.74% | -13.64% |
| 04-19 | Jianmin Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 04-16 | Jianmin Pharma Gets Nod to Market Asthma Drug | MT |
| Sales 2024 * | 4.93B 682M 54.27B | Sales 2025 * | 5.68B 785M 62.52B | Capitalization | 8.56B 1.18B 94.26B |
|---|---|---|---|---|---|
| Net income 2024 * | 619M 85.59M 6.81B | Net income 2025 * | 768M 106M 8.45B | EV / Sales 2024 * | 1.74 x |
| Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 1.51 x |
| P/E ratio 2024 * |
14
x | P/E ratio 2025 * |
11.3
x | Employees | 2,497 |
| Yield 2024 * |
2.77% | Yield 2025 * |
3.39% | Free-Float | 69.14% |
More Fundamentals
* Assessed data
More news
| 1 day | +1.28% | ||
| 1 week | -0.74% | ||
| Current month | -2.46% | ||
| 1 month | -1.33% | ||
| 3 months | +8.93% | ||
| 6 months | -6.30% | ||
| Current year | -13.64% |
1 week
52.96
58.17
1 month
51.3260.23
Current year
42.2468.06
1 year
42.2479.89
3 years
33.8286.78
5 years
14.4086.78
10 years
13.6986.78
| Managers | Title | Age | Since |
|---|---|---|---|
Jun Wang
CEO | Chief Executive Officer | 48 | 08/09/20 |
Zhao Yang Cheng
DFI | Director of Finance/CFO | 52 | 01/01/18 |
Qin He
CHM | Chairman | 64 | 31/12/03 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Qin He
CHM | Chairman | 64 | 31/12/03 |
Shu Qu Li
BRD | Director/Board Member | 53 | 04/09/19 |
Rong Pei
BRD | Director/Board Member | 53 | 02/08/11 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 28/04/24 | 56.35 | +1.28% | 2 283 779 |
| 26/04/24 | 55.64 | -1.50% | 2,029,011 |
| 25/04/24 | 56.49 | +0.21% | 2,721,052 |
| 24/04/24 | 56.37 | -0.30% | 2,662,781 |
| 23/04/24 | 56.54 | +4.43% | 4,142,820 |
End-of-day quote Shanghai S.E., April 28, 2024
More quotes
JIANMIN PHARMACEUTICAL GROUP CO., LTD., formerly Wuhan Jianmin Pharmaceutical Groups Co. Ltd, is a China-based company, principally engaged in the research and development, manufacture, wholesale and retailing of pharmaceuticals. The Company operates its businesses through two segments, including Pharmaceutical Industry and Pharmaceutical Business. The Pharmaceutical Industry segment is engaged in the research and development and manufacture of pharmaceuticals. Its products are mainly applied in children, women and the elderly, among others. The Pharmaceutical Business segment is engaged in the wholesale and retailing of pharmaceuticals. Its products include traditional Chinese medicine, Western medicine, health products, medical equipment and chemical agents. It distributes its products mainly in domestic market.
Sector
Pharmaceuticals
Calendar
13/08/2024
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
56.35
CNY
Average target price
87.74
CNY
Spread / Average Target
+55.71%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -13.64% | 1.17B | |
| +25.81% | 661B | |
| +26.74% | 566B | |
| -6.69% | 352B | |
| +18.81% | 332B | |
| +3.37% | 283B | |
| +13.43% | 231B | |
| +4.71% | 200B | |
| -9.53% | 195B | |
| -4.32% | 145B |
- Stock Market
- Equities
- 600976 Stock
